Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM

Manali Kamdar, Scott Solomon, Jon Arnason, Patrick Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew Lunning, Vincent Ribrag, Yi Lin, Rashmi Bhatnagar, Sandrine Montheard, Jeremy Abramson

Blood (2025) 146 (Supplement 1): 3710.

https://doi.org/10.1182/blood-2025-3710

Published: 2025

Journal Articles

Outpatient (OP) use of lisocabtagene maraleucel (liso-cel) in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): Real-world data from the CIBMTR registry

Krish Patel, Matthew Lunning, Konstantinos Sdrimas, Minoo Battiwalla, Uttam Rao, Yi Lin, Sami Ibrahimi, Jennifer L. Crombie, Sairah Ahmed, Iris Isufi, Matthew Frigault, David Bernasconi, Debasmita Roy, Marcelo Pasquini, Bradley D. Hunter

Blood (2025) 146 (Supplement 1): 5482.

https://doi.org/10.1182/blood-2025-5482

Published: 2025

Journal Articles

Pre-CAR-T pulmonary function test and respiratory comorbidities have limited predictive value for survival, toxicities, and respiratory complications

Yuanli Lei, Muhammad Atif Khan, Aqsa Ashraf, Noha Soror, Muhammad Salman Faisal, Jennifer Holter-Chakrabarty, Adam Asch, Forat Lutfi, Rachel Dileo, Sami Ibrahimi, Manu Pandey, Mohamad Khawandanah, Silas Day, Huimin Wu, Prerna Mewawalla, Nausheen Ahmed, Taha Al-Juhaishi

Blood (2025) 146 (Supplement 1): 2373.

https://doi.org/10.1182/blood-2025-2373

Published: 2025

Journal Articles

Recombinant ADAMTS13 prophylaxis in patients with congenital thrombotic thrombocytopenic purpura: Final analysis from A phase 3 randomized, controlled study

Blood (2025) 146 (Supplement 1): 848.

https://doi.org/10.1182/blood-2025-848

Published: 2025

Journal Articles

Gastrointestinal and hepatobiliary toxicities associated with bispecific antibody therapy in hematologic malignancies: A retrospective single-center study.

Bibi Maryam, Anoushka Mullasseril, Mahnoor Khan, Adolfo Diaz Barba, Yusra Nasir, Satya Sai Venkata Lakshmi Arepalli, Aminah Tayyab, Ujjwal Soni, Kolton Kardokus, Ijlal Akbar Ali, Taha Al-Juhaishi, Sami Ibrahimi, Muhammad Salman Faisal

Blood (2025) 146 (Supplement 1): 8048.

https://doi.org/10.1182/blood-2025-8048

Published: 2025

Journal Articles

Outpatient administration of epcoritamab monotherapy for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Results from EPCORE NHL-6 by race and ethnicity

Blood (2025) 146 (Supplement 1): 1959.

https://doi.org/10.1182/blood-2025-1959

Published: 2025

Journal Articles

Fungal infections following chimeric antigen receptor T-cell (CAR-T) cell therapy: A retrospective case-control study in the south-central US

Bibi Maryam, Adolfo Diaz Barba, Aminah Tayyab, Hussnain Zafar, Satya Sai Venkata Lakshmi Arepalli, Niveditha Popuri, Ayesha Aijaz, Noha Soror, Aqsa Ashraf, Michael Machiorlatti, Emily Siegrist, Sami Ibrahimi, Taha Al-Juhaishi, Joseph Sassine

Blood (2025) 146 (Supplement 1): 2781.

https://doi.org/10.1182/blood-2025-2781

Published: 2025

Journal Articles

Outpatient administration of idecabtagene vicleucel: Predictors of hospitalization and impact on survival outcomes

Aqsa Ashraf, Noha Soror, Ayesha Aijaz, Muhammad Salman Faisal, Zimu Gong, Manu Pandey, Sami Ibrahimi, Adam Asch, Mohamad Khawandanah, Jennifer Holter-Chakrabarty, Silas Day, Michael Machiorlatti, Taha Al-Juhaishi

Blood (2025) 146 (Supplement 1): 7598.

https://doi.org/10.1182/blood-2025-7598

Published: 2025

Journal Articles

CTEP 10590, NORM: Nodular Lymphocyte Predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase II Trial with Either Rituximab or Mosunetuzumab

Raphael Steiner, Allison M. Bock, Alex F. Herrera, Omer Zulfa, Marc Hoffmann, Sami Ibrahimi, Natalie Galanina, Hun Ju Lee, Michael Green, Ruitao Lin, Chelsea C. Pinnix, Alison Moskowitz, Joachim Yahalom, Dai Chihara

Blood (2024) 144 (Supplement 1): 4434.2.

https://doi.org/10.1182/blood-2024-202516

Published: 2024

Journal Articles

Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study

Blood (2024) 144 (Supplement 1): 72.

https://doi.org/10.1182/blood-2024-199813

Published: 2024

Journal Articles

Phase 1 Study of Escalating Doses of Ibrutinib in Teddi-R with Isavuconazole for Relapsed and Refractory Primary DLBCL of the CNS

Blood (2024) 144 (Supplement 1): 3122.

https://doi.org/10.1182/blood-2024-199168

Published: 2024

Journal Articles

Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412)

Catherine S Diefenbach, Opeyemi Jegede, Stephen M Ansell, Christian Steidl, Yasodha Natkunam, David W. Scott, Neha Mehta-Shah, Jennifer E Amengual, Christopher J. Forlenza, Peter D. Cole, Nancy L. Bartlett, Kevin A. David, Ranjana H. Advani, Richard F. Ambinder, Sachdev Thomas, Sami Ibrahimi, Brad S. Kahl

Blood (2023) 142 (Supplement 1): 607.

https://doi.org/10.1182/blood-2023-184531

Published: 2023

Journal Articles

Phase 2 Response-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, and Rituximab (TEDDI-R) for Secondary CNS Lymphoma

Blood (2023) 142 (Supplement 1): 854.

https://doi.org/10.1182/blood-2023-177994

Published: 2023

Journal Articles

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Jeremy S. Abramson, Scott R. Solomon, Jon Arnason, Patrick B. Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew Lunning, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Ken Ogasawara, Manali Kamdar

Blood (2023) 141 (14): 1675–1684.

https://doi.org/10.1182/blood.2022018730

Published: 2023

Includes: Supplemental data

Journal Articles

Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 Transform Study

Jeremy S. Abramson, Scott R. Solomon, Jon E. Arnason, Patrick B. Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew A. Lunning, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Manali Kamdar

Blood (2022) 140 (Supplement 1): 1581–1583.

https://doi.org/10.1182/blood-2022-159702

Published: 2022

Journal Articles

Long-Term Follow-up of Patients with Congenital Thrombotic Thrombocytopenia Purpura Receiving Plasma-Derived Factor VIII Containing (Koate®)

Tammuella Chrisentery-Singleton, Lisa N Boggio, Manuel Carcao, Sami Ibrahimi, Osman Khan, Arash Mahajerin, Anita Rajasekhar, Vivek Sharma, MacGregor Steele, Marcela Torres, Shannon L Carpenter

Blood (2022) 140 (Supplement 1): 5644–5646.

https://doi.org/10.1182/blood-2022-162506

Published: 2022

Journal Articles

Novel Home-Based Transfusion Model of Palliative Care in Malignant Hematology

Blood (2022) 140 (Supplement 1): 11024–11025.

https://doi.org/10.1182/blood-2022-162527

Published: 2022

Journal Articles

Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study

Blood (2021) 138 (Supplement 1): 91.

https://doi.org/10.1182/blood-2021-147913

Published: 2021

Journal Articles

Successful Development of an Outpatient Chimeric Antigen Receptor (CAR) T Cell Therapy Program

Azra Borogovac, Amany R. Keruakous, Michelle Bycko, Jennifer Holter Chakrabarty, Sami Ibrahimi, Mohamad O. Khawandanah, George B. Selby, Carrie Yuen, Sarah A. Schmidt, Taha Al-Juhaishi, Matthew Wieduwilt, Adam S. Asch

Blood (2021) 138 (Supplement 1): 4821.

https://doi.org/10.1182/blood-2021-153457

Published: 2021

Journal Articles

Primary Mantle Cell Lymphoma of the Tonsil: A Case Series

Sami Ibrahimi, MD, Pragathi Balakrishna, MD, Amany R. Keruakous, MD

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-143156

Published: 2020

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM

Outpatient (OP) use of lisocabtagene maraleucel (liso-cel) in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): Real-world data from the CIBMTR registry

Pre-CAR-T pulmonary function test and respiratory comorbidities have limited predictive value for survival, toxicities, and respiratory complications

Recombinant ADAMTS13 prophylaxis in patients with congenital thrombotic thrombocytopenic purpura: Final analysis from A phase 3 randomized, controlled study

Gastrointestinal and hepatobiliary toxicities associated with bispecific antibody therapy in hematologic malignancies: A retrospective single-center study.

Outpatient administration of epcoritamab monotherapy for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Results from EPCORE NHL-6 by race and ethnicity

Fungal infections following chimeric antigen receptor T-cell (CAR-T) cell therapy: A retrospective case-control study in the south-central US

Outpatient administration of idecabtagene vicleucel: Predictors of hospitalization and impact on survival outcomes

CTEP 10590, NORM: Nodular Lymphocyte Predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase II Trial with Either Rituximab or Mosunetuzumab

Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study

Phase 1 Study of Escalating Doses of Ibrutinib in Teddi-R with Isavuconazole for Relapsed and Refractory Primary DLBCL of the CNS

Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412)

Phase 2 Response-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, and Rituximab (TEDDI-R) for Secondary CNS Lymphoma

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Long-Term Follow-up of Patients with Congenital Thrombotic Thrombocytopenia Purpura Receiving Plasma-Derived Factor VIII Containing (Koate®)

Novel Home-Based Transfusion Model of Palliative Care in Malignant Hematology

Successful Development of an Outpatient Chimeric Antigen Receptor (CAR) T Cell Therapy Program

Primary Mantle Cell Lymphoma of the Tonsil: A Case Series

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only